{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:51:01Z","timestamp":1777884661164,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Patients undergoing transplantation experience higher rates of venous thromboembolism and non-valvular atrial fibrillation (NVAF) compared with the general population. Anticoagulation decisions in this patient population are complex. A national survey on direct-acting oral anticoagulant practices demonstrated significant heterogeneity, in the setting of drug-drug interactions.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The aim of this study was to evaluate the anticoagulation practices of clinicians caring for solid organ transplant patients.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A 15-question survey consisting of 7 demographic questions and 8 unique patient cases was distributed via email Listserv of several professional transplantation organizations. Each case question asked the participant to select an anticoagulant regimen depending on: (1) indication for anticoagulation, (2) renal function, and (3) drug-drug interactions. Participants selected one of the following options: apixaban, dabigatran, enoxaparin, rivaroxaban, warfarin, or write in an alternative option. Descriptive statistics were used to analyze survey results.\n                    <jats:bold>Results:<\/jats:bold>\n                    Fifty participants completed 4 or more (\u226550%) of the case-based survey questions and were included in the analysis. Ninety-four percent of participants were pharmacists, representing 43 transplant centers. Fifty-one percent of responders preferred warfarin for the indication of NVAF. Apixaban was preferred in patients with new or previous deep vein thrombosis\/pulmonary embolism (51%). Fifty-four percent of respondents preferred warfarin in questions in renal dysfunction. In scenarios involving a mild-moderate CYP3A4 inhibitor azole antifungal, 61% of respondents preferred apixaban, with 64% of those selecting a standard dose regimen (vs a reduced dose regimen). Participants preferred warfarin (57%) in scenarios with a strong CYP3A4 inhibitor.\n                    <jats:bold>Conclusion and Relevance:<\/jats:bold>\n                    The results of our survey demonstrated a high degree of variation when selecting anticoagulation strategies in complex clinical scenarios involving transplant patients.\n                  <\/jats:p>","DOI":"10.1177\/87551225251348830","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:16:29Z","timestamp":1751260589000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Effect of Concomitant Azoles on Anticoagulant Prescribing Practices in Transplant Patients: A National Survey of Clinicians"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2415-1317","authenticated-orcid":false,"given":"Kristina M.","family":"Burroughs","sequence":"first","affiliation":[{"name":"Inova Fairfax Hospital, Falls Church, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3804-6517","authenticated-orcid":false,"given":"Alicia B.","family":"Lichvar","sequence":"additional","affiliation":[{"name":"University of California, Irvine, Orange, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-5862","authenticated-orcid":false,"given":"Lara M.","family":"Groetzinger","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Horn","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo J.","family":"Iasella","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-2004","authenticated-orcid":false,"given":"Cody A.","family":"Moore","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana R.","family":"Pierce","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Sacha","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Rivosecchi","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.02.032"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2015.05.009"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2016.05.043"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.09.039"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0035"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2015.05.095"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001977"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.06.060"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.013"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13599"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.12.007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003168"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13756"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2485"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14296"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.11.032"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002305"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000956"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.633"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.633"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.13883"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13853"},{"key":"e_1_3_3_25_2","volume-title":"Pradaxa (dabigatran etexilate mesylate)","author":"Boehringer Ingelheim Pharmaceuticals, Inc","year":"2024","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran etexilate mesylate) [package insert]. U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00340118"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071484"},{"key":"e_1_3_3_30_2","unstructured":"Bristol-Myers Squibb Company. Eliquis (apixaban) [package insert]. U.S. Food and Drug Administration; December 2022."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014108"},{"key":"e_1_3_3_32_2","unstructured":"Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) [package insert]. U.S. Food and Drug Administration; 2016."}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251348830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225251348830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251348830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:19Z","timestamp":1777602799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225251348830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/87551225251348830"],"URL":"https:\/\/doi.org\/10.1177\/87551225251348830","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}